Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.
The hypothesis that cortisol is the functioning mineralocorticoid in the syndrome of apparent mineralocorticoid excess was tested by suppressing its secretion with dexamethasone. The subjects were two siblings with the type 2 form of this syndrome in which the defect in the peripheral metabolism of cortisol lies predominantly in ring A reduction but not in 11 beta-hydroxy dehydrogenation of cortisol to cortisone. Low dosage dexamethasone improved the hypokalemia within several days and hypertension was corrected after 3 weeks of treatment. Mineralocorticoid manifestations remained in remission during 10 yr of therapy with the synthetic glucocorticoid during which normal growth and development were restored. The effectiveness of dexamethasone supports the hypothesis that cortisol is the functioning mineralocorticoid in the AME syndrome.
Tedde
R
R
Clinica Medica, Università di Sassari, Italy.
Pala
A
A
Melis
A
A
Ulick
S
S
D000293:Adolescent; D003348:Cortisone / Q000378:metabolism; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008901:Mineralocorticoids; D011188:Potassium / Q000097:blood; D013577:Syndrome
D008901:Mineralocorticoids; D003907:Dexamethasone; D011188:Potassium; D003348:Cortisone; D006854:Hydrocortisone